Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir
about
Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance MutationsHIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant VariantsDistinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA ProteinTiming the emergence of resistance to anti-HIV drugs with large genetic barriersProteochemometric modeling of the bioactivity spectra of HIV-1 protease inhibitors by introducing protein-ligand interaction fingerprintIdentification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screeningComputational models of HIV-1 resistance to gene therapy elucidate therapy design principlesTribute to Mark WainbergEfficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesExploring the complexity of the HIV-1 fitness landscape.Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsTipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialExperimental and computational studies on the effects of valganciclovir as an antiviral drug on calf thymus DNA.Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.Tipranavir: a protease inhibitor for HIV salvage therapy.Review of tipranavir in the treatment of drug-resistant HIV.Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patientsNonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges.Antiretroviral drug resistance in human immunodeficiency virus type 2.Human Immunodeficiency Virus Gag and protease: partners in resistance.Carbon-carbon bond cleavage and formation reactions in drug metabolism and the role of metabolic enzymes.Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDSGenotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.HIV-1 protease mutations and protease inhibitor cross-resistance.Possible paths and potential barriers to successfully modeling drug resistance.α-pyrones and their hydroxylated analogs as promising scaffolds against Mycobacterium tuberculosis.Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
P2860
Q27644072-7CC35535-99F3-4AA1-A304-745D137798D2Q27650325-4E478389-8EC8-4A2F-A397-EF8CD0E529D4Q27678471-EF5304C2-BCC7-4A83-8C62-704FBC4E94B2Q28474857-3CF8E26A-228A-4AC4-9239-7C7FBB7801A3Q28481635-4F4A139E-C352-4828-9071-D91ACBB3D64DQ28485115-673517EB-2995-48C7-97FA-AA5D9B86A9C1Q33658642-45ED59D9-099E-45C7-A123-8D5B6FBA06ADQ33846297-E7346613-567F-454B-B91E-7A7DA8DF604BQ34005107-1827B48D-42B6-4CBE-9667-6ED0B0D4C242Q34102058-88E9A7B4-7E98-4EDC-A8D2-CA8035193989Q34192888-CDF2A347-E30C-4CF3-9D36-45093149CA04Q34352000-6791F1C4-A56B-44CE-8C6C-3CF91C5F19D9Q35636029-681804D5-95F4-4B8E-8685-9162F6076CCDQ35885190-CEB836B9-CA1C-44DE-BD24-3FB3F828F7A4Q36167461-77CFC545-AB76-4D4A-AF3D-0CF23C40CDC9Q36414526-13BDD89B-1267-475C-8D27-815BAB1258C1Q36482890-FC79A1BC-3259-4250-B4CE-DD2BE6297F14Q36513619-1B59DA1F-ABC4-434E-81B3-4D313E9BA344Q36642990-FBA24423-0730-490D-A3C6-E5E69C852D7CQ36870850-62D76EE8-EA56-4E46-A053-58CDDC7651A6Q37409842-03CAE048-A2C0-47F4-94D3-92125A17D6C3Q37415603-6ED4852E-AE91-4319-B3F4-1ADE9ABB43E9Q37496287-6E7C1554-C9FE-4F7B-84C9-800CAFF5AC23Q38032330-038AF567-D01E-44B6-BC32-05C8A00FFA3AQ38590451-8F7D96C7-C731-4109-8AFE-1A4EAFF693EBQ38708006-03EB645D-4F3C-4874-9484-C749F2B2C797Q39290078-292E98E8-05FC-4EFA-BDFB-83B2605497C0Q42125534-9CCB1999-28EF-48B1-9E6E-4A6CB4F47466Q42421248-CB626A66-51C3-47D9-A26C-A439AE326CC6Q43833882-95127AFF-7F3C-40A3-9C72-A0255073EE03Q47873412-F5080EEC-0EFD-41AC-8562-A5E4D9E996ECQ52671185-81ED4B3A-A898-428A-A20C-64A1A44EEA74
P2860
Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Selection and characterization ...... protease inhibitor tipranavir
@ast
Selection and characterization ...... protease inhibitor tipranavir
@en
Selection and characterization ...... protease inhibitor tipranavir
@nl
type
label
Selection and characterization ...... protease inhibitor tipranavir
@ast
Selection and characterization ...... protease inhibitor tipranavir
@en
Selection and characterization ...... protease inhibitor tipranavir
@nl
prefLabel
Selection and characterization ...... protease inhibitor tipranavir
@ast
Selection and characterization ...... protease inhibitor tipranavir
@en
Selection and characterization ...... protease inhibitor tipranavir
@nl
P2093
P1433
P1476
Selection and characterization ...... protease inhibitor tipranavir
@en
P2093
Elizabeth Wardrop
Lise Bourgon
Louise Doyon
Michael G Cordingley
Sonia Tremblay
P356
10.1016/J.ANTIVIRAL.2005.07.003
P407
P577
2005-10-01T00:00:00Z